title: Safety of allergen immunotherapy: a review of premedication and dose adjustment.
abstract: From the first allergen immunotherapy proposed in the early 1900s to the present day, numerous studies have proven the efficacy of allergen immunotherapy for the treatment of allergic rhinitis, allergic conjunctivitis, allergic asthma and stinging insect hypersensitivity. The major risk, however small, with allergen immunotherapy is anaphylaxis. There has been considerable interest and debate regarding risk factors for immunotherapy reactions (local and systemic) and interventions to reduce the occurrence of these reactions. One of these interventions that is especially debated regards dose adjustment for various reasons, but in particular for local reactions. In this review, we discuss the safety of immunotherapy and provide a comprehensive review of the literature regarding immunotherapy schedules and doses.
authors.affiliation: Division of Clinical Immunology & Allergy, Department of Medicine, University of Mississippi Medical Center, Jackson, MS 39216-4505, USA.
authors.forename: A Erika
authors.initials: AE
authors.lastname: Morris
authors.forename: Gailen D
authors.initials: GD
authors.lastname: Marshall
mesh_terms: D000485:Allergens / Q000276:immunology / Q000627:therapeutic use*; D000707:Anaphylaxis / Q000276:immunology / Q000628:therapy*; D000818:Animals; D004305:Dose-Response Relationship, Drug; D004306:Dose-Response Relationship, Immunologic; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods*; D012307:Risk Factors; D012449:Safety
chemical_list: D000485:Allergens